Study aid only. Verify against current guidelines, primary literature, staging manuals, and prescribing information before clinical use.

← All algorithms  ·  Related notes →

Hemophilia A / B — Management

First-line Second-line SECOND-LINE Hemophilia A or B (by factor) Hemophilia A — no inhibitor Hemophilia B With inhibitors Prophylaxis Emicizumab HAVEN ↗ Replacement Factor VIII concentrate standard / extended half-life Replacement Factor IX concentrate prophylaxis Hem A Emicizumab effective with inhibitors ↗ Bleeds Bypassing agents (aPCC / rFVIIa) acute bleeding Eradicate Immune tolerance induction high-dose factor